This study not only suggested PAR2 as a novel therapeutical target for gefitinib resistance but also uncovered a new receptor-mediated mechanism for overcoming NSCLC resistant to gefitinib. The gene discussed is F2RL1; the disease is non-small cell lung carcinoma.